Download presentation
Presentation is loading. Please wait.
Published byThéophile Thibodeau Modified over 5 years ago
1
Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF inhibitors, NSAIDs with synthetic DMARDs, or monotherapies with NSAIDs, TNF inhibitors or synthetic DMARDS, respectively. Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF inhibitors, NSAIDs with synthetic DMARDs, or monotherapies with NSAIDs, TNF inhibitors or synthetic DMARDS, respectively. (D) Proportions of poorly rated physician-reported and patient-reported outcomes (scores *4–10 or **7–10 on a numerical rating scale with range 0–10). NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor; sDMARD, synthetic disease-modifying antirheumatic drug. Dörte Huscher et al. RMD Open 2015;1:e000033 Copyright © BMJ Publishing Group & EULAR. All rights reserved.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.